|
1
|
Suh YS, Joung JY, Kim SH, Seo HK, Chung J
and Lee KH: Establishment and application of prostate cancer
circulating tumor cells in the Era of precision medicine. Biomed
Res Int. 2017:72063072017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yamoah K, Beecham K, Hegarty SE, Hyslop T,
Showalter T and Yarney J: Early results of prostate cancer
radiation therapy: An analysis with emphasis on research strategies
to improve treatment delivery and outcomes. BMC Cancer. 13:232013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pinkawa M, Schoth F, Böhmer D, Hatiboglu
G, Sharabi A, Song D and Eble MJ: Current standards and future
directions for prostate cancer radiation therapy. Expert Rev
Anticancer Ther. 13:75–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barret E, Harvey-Bryan KA, Sanchez-Salas
R, Rozet F, Galiano M and Cathelineau X: How to diagnose and treat
focal therapy failure and recurrence? Curr Opin Urol. 24:241–246.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qin J, Lee HJ, Wu SP, Lin SC, Lanz RB,
Creighton CJ, DeMayo FJ, Tsai SY and Tsai MJ: Androgen
deprivation-induced NCoA2 promotes metastatic and
castration-resistant prostate cancer. J Clin Invest. 124:5013–5026.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tattermusch A and Brockdorff N: A scaffold
for X chromosome inactivation. Hum Genet. 130:247–253. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye CS, Zhou DN, Yang QQ and Deng YF:
Silencing SATB1 influences cell invasion, migration, proliferation,
and drug resistance in nasopharyngeal carcinoma. Int J Clin Exp
Pathol. 7:914–922. 2014.PubMed/NCBI
|
|
8
|
Zhang L, Cheng F, He R, Chen H, Liu Y and
Sun J: Inhibition of SATB1 by shRNA suppresses the proliferation of
cutaneous malignant melanoma. Cancer Biother Radiopharm. 29:77–82.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang H, Su X, Guo L, Zhong L, Li W, Yue
Z, Wang X, Mu Y, Li X, Li R and Wang Z: Silencing SATB1 inhibits
the malignant phenotype and increases sensitivity of human
osteosarcoma U2OS cells to arsenic trioxide. Int J Med Sci.
11:1262–1269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang B, Zhou H, Wang X and Liu Z:
Silencing SATB1 with siRNA inhibits the proliferation and invasion
of small cell lung cancer cells. Cancer Cell Int. 13(8)2013.
|
|
11
|
Mao L, Yang C, Wang J, Li W, Wen R, Chen J
and Zheng J: SATB1 is overexpressed in metastatic prostate cancer
and promotes prostate cancer cell growth and invasion. J Transl
Med. 11:1112013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Betáková T and Svančarová P: Role and
application of RNA interference in replication of influenza
viruses. Acta Virol. 57:97–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song Y, Liu C, Liu X, Trottier J, Beaudoin
M, Zhang L, Pope C, Peng G, Barbier O, Zhong X, et al: H19 promotes
cholestatic liver fibrosis by preventing ZEB1-mediated inhibition
of epithelial cell adhesion molecule. Hepatology. 66:1183–1196.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Chen H, Xue L, Pang X, Zhang X, Zhu
Z, Zhu W, Wang Z and Wu H: p53 performs an essential role in
mediating the oncogenic stimulus triggered by loss of expression of
neurofibromatosis type 2 during in vitro tumor progression. Oncol
Lett. 14:2223–2231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He
L, Wang Y, Zhang J, Zhang Z, Huiwang J, et al: Potent antitumour
activity of oncolytic adenovirus expressing mda-7/IL-24 for
colorectal cancer. Hum Gene Ther. 16:845–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng Y, Liu W, Guo L and Yang X: The
expression level of miR-203 in patients with gastric cancer and its
clinical significance. Pathol Res Pract. 213:1515–1518. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roomi MW, Kalinovsky T, Rath M and
Niedzwiecki A: A nutrient mixture inhibits glioblastoma xenograft
U-87 MG growth in male nude mice. Exp Oncol. 38:54–56.
2016.PubMed/NCBI
|
|
18
|
Chen CB, Eurich DT, Majumdar SR and
Johnson JA: Risk of prostate cancer across different racial/ethnic
groups in men with diabetes: A retrospective cohort study. Diabet
Med. 35:107–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H,
He J, Han P and Tian D: Upregulation of SATB1 promotes tumor growth
and metastasis in liver cancer. Liver Int. 32:1064–1078. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Hu SC, Yang CS, Chen JC, Zheng JN,
Sun XQ and Wang JQ: Inhibition of prostate cancer cell growth in
vivo with short hairpin RNA targeting SATB1. Oncol Lett.
14:6592–6596. 2017.PubMed/NCBI
|
|
21
|
Han HJ, Russo J, Kohwi Y and
Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote
breast tumor growth and metastasis. Nature. 452:187–193. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao LJ, Zhang J, Liu N, Fan L, Yang DR,
Xue BX, Shan YX and Zheng JN: Oncolytic virus carrying shRNA
targeting SATB1 inhibits prostate cancer growth and metastasis.
Tumour Biol. 36:9073–9081. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi JW, Lee JS, Kim SW and Yun CO:
Evolution of oncolytic adenovirus for cancer treatment. Adv Drug
Deliv Rev. 64:720–729. 2012. View Article : Google Scholar : PubMed/NCBI
|
